Outcome of Transplantation for Myelofibrosis

Karen K. Ballen, Smriti Shrestha, Kathleen A. Sobocinski, Mei Jie Zhang, Asad Bashey, Brian J. Bolwell, Francisco Cervantes, Steven M. Devine, Robert Peter Gale, Vikas Gupta, Theresa E. Hahn, William J. Hogan, Nicolaus Kröger, Mark R. Litzow, David I. Marks, Richard Maziarz, Philip L. McCarthy, Gary Schiller, Harry C. Schouten, Vivek RoyPeter H. Wiernik, Mary M. Horowitz, Sergio A. Giralt, Mukta Arora

Research output: Contribution to journalArticle

159 Citations (Scopus)

Abstract

Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small series have reported long-term disease-free survival (DSF) after allogeneic hematopoietic cell transplantation (HCT). In this study, we analyze the outcomes of 289 patients receiving allogeneic transplantation for primary myelofibrosis between 1989 and 2002, from the database of the Center for International Bone Marrow Transplant Research (CIBMTR). The median age was 47 years (range: 18-73 years). Donors were HLA identical siblings in 162 patients, unrelated individuals in 101 patients, and HLA nonidentical family members in 26 patients. Patients were treated with a variety of conditioning regimens and graft-versus-host disease (GVHD) prophylaxis regimens. Splenectomy was performed in 65 patients prior to transplantation. The 100-day treatment-related mortality was 18% for HLA identical sibling transplants, 35% for unrelated transplants, and 19% for transplants from alternative related donors. Corresponding 5-year overall survival (OS) rates were 37%, 30%, and 40%, respectively. DFS rates were 33%, 27%, and 22%, respectively. DFS for patients receiving reduced-intensity transplants was comparable: 39% for HLA identical sibling donors and 17% for unrelated donors at 3 years. In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival (RFS) in about one-third of patients.

Original languageEnglish (US)
Pages (from-to)358-367
Number of pages10
JournalBiology of Blood and Marrow Transplantation
Volume16
Issue number3
DOIs
StatePublished - Mar 2010

Fingerprint

Primary Myelofibrosis
Transplantation
Transplants
Siblings
Homologous Transplantation
Tissue Donors
Myeloproliferative Disorders
Unrelated Donors
Cell Transplantation
Graft vs Host Disease
Splenectomy
Disease-Free Survival
Survival Rate
Bone Marrow
Databases
Recurrence
Survival
Mortality

Keywords

  • Allogeneic transplantation
  • Myelofibrosis

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Ballen, K. K., Shrestha, S., Sobocinski, K. A., Zhang, M. J., Bashey, A., Bolwell, B. J., ... Arora, M. (2010). Outcome of Transplantation for Myelofibrosis. Biology of Blood and Marrow Transplantation, 16(3), 358-367. https://doi.org/10.1016/j.bbmt.2009.10.025

Outcome of Transplantation for Myelofibrosis. / Ballen, Karen K.; Shrestha, Smriti; Sobocinski, Kathleen A.; Zhang, Mei Jie; Bashey, Asad; Bolwell, Brian J.; Cervantes, Francisco; Devine, Steven M.; Gale, Robert Peter; Gupta, Vikas; Hahn, Theresa E.; Hogan, William J.; Kröger, Nicolaus; Litzow, Mark R.; Marks, David I.; Maziarz, Richard; McCarthy, Philip L.; Schiller, Gary; Schouten, Harry C.; Roy, Vivek; Wiernik, Peter H.; Horowitz, Mary M.; Giralt, Sergio A.; Arora, Mukta.

In: Biology of Blood and Marrow Transplantation, Vol. 16, No. 3, 03.2010, p. 358-367.

Research output: Contribution to journalArticle

Ballen, KK, Shrestha, S, Sobocinski, KA, Zhang, MJ, Bashey, A, Bolwell, BJ, Cervantes, F, Devine, SM, Gale, RP, Gupta, V, Hahn, TE, Hogan, WJ, Kröger, N, Litzow, MR, Marks, DI, Maziarz, R, McCarthy, PL, Schiller, G, Schouten, HC, Roy, V, Wiernik, PH, Horowitz, MM, Giralt, SA & Arora, M 2010, 'Outcome of Transplantation for Myelofibrosis', Biology of Blood and Marrow Transplantation, vol. 16, no. 3, pp. 358-367. https://doi.org/10.1016/j.bbmt.2009.10.025
Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ et al. Outcome of Transplantation for Myelofibrosis. Biology of Blood and Marrow Transplantation. 2010 Mar;16(3):358-367. https://doi.org/10.1016/j.bbmt.2009.10.025
Ballen, Karen K. ; Shrestha, Smriti ; Sobocinski, Kathleen A. ; Zhang, Mei Jie ; Bashey, Asad ; Bolwell, Brian J. ; Cervantes, Francisco ; Devine, Steven M. ; Gale, Robert Peter ; Gupta, Vikas ; Hahn, Theresa E. ; Hogan, William J. ; Kröger, Nicolaus ; Litzow, Mark R. ; Marks, David I. ; Maziarz, Richard ; McCarthy, Philip L. ; Schiller, Gary ; Schouten, Harry C. ; Roy, Vivek ; Wiernik, Peter H. ; Horowitz, Mary M. ; Giralt, Sergio A. ; Arora, Mukta. / Outcome of Transplantation for Myelofibrosis. In: Biology of Blood and Marrow Transplantation. 2010 ; Vol. 16, No. 3. pp. 358-367.
@article{83a7c8b0211748c694b9f07906ea8a9c,
title = "Outcome of Transplantation for Myelofibrosis",
abstract = "Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small series have reported long-term disease-free survival (DSF) after allogeneic hematopoietic cell transplantation (HCT). In this study, we analyze the outcomes of 289 patients receiving allogeneic transplantation for primary myelofibrosis between 1989 and 2002, from the database of the Center for International Bone Marrow Transplant Research (CIBMTR). The median age was 47 years (range: 18-73 years). Donors were HLA identical siblings in 162 patients, unrelated individuals in 101 patients, and HLA nonidentical family members in 26 patients. Patients were treated with a variety of conditioning regimens and graft-versus-host disease (GVHD) prophylaxis regimens. Splenectomy was performed in 65 patients prior to transplantation. The 100-day treatment-related mortality was 18{\%} for HLA identical sibling transplants, 35{\%} for unrelated transplants, and 19{\%} for transplants from alternative related donors. Corresponding 5-year overall survival (OS) rates were 37{\%}, 30{\%}, and 40{\%}, respectively. DFS rates were 33{\%}, 27{\%}, and 22{\%}, respectively. DFS for patients receiving reduced-intensity transplants was comparable: 39{\%} for HLA identical sibling donors and 17{\%} for unrelated donors at 3 years. In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival (RFS) in about one-third of patients.",
keywords = "Allogeneic transplantation, Myelofibrosis",
author = "Ballen, {Karen K.} and Smriti Shrestha and Sobocinski, {Kathleen A.} and Zhang, {Mei Jie} and Asad Bashey and Bolwell, {Brian J.} and Francisco Cervantes and Devine, {Steven M.} and Gale, {Robert Peter} and Vikas Gupta and Hahn, {Theresa E.} and Hogan, {William J.} and Nicolaus Kr{\"o}ger and Litzow, {Mark R.} and Marks, {David I.} and Richard Maziarz and McCarthy, {Philip L.} and Gary Schiller and Schouten, {Harry C.} and Vivek Roy and Wiernik, {Peter H.} and Horowitz, {Mary M.} and Giralt, {Sergio A.} and Mukta Arora",
year = "2010",
month = "3",
doi = "10.1016/j.bbmt.2009.10.025",
language = "English (US)",
volume = "16",
pages = "358--367",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Outcome of Transplantation for Myelofibrosis

AU - Ballen, Karen K.

AU - Shrestha, Smriti

AU - Sobocinski, Kathleen A.

AU - Zhang, Mei Jie

AU - Bashey, Asad

AU - Bolwell, Brian J.

AU - Cervantes, Francisco

AU - Devine, Steven M.

AU - Gale, Robert Peter

AU - Gupta, Vikas

AU - Hahn, Theresa E.

AU - Hogan, William J.

AU - Kröger, Nicolaus

AU - Litzow, Mark R.

AU - Marks, David I.

AU - Maziarz, Richard

AU - McCarthy, Philip L.

AU - Schiller, Gary

AU - Schouten, Harry C.

AU - Roy, Vivek

AU - Wiernik, Peter H.

AU - Horowitz, Mary M.

AU - Giralt, Sergio A.

AU - Arora, Mukta

PY - 2010/3

Y1 - 2010/3

N2 - Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small series have reported long-term disease-free survival (DSF) after allogeneic hematopoietic cell transplantation (HCT). In this study, we analyze the outcomes of 289 patients receiving allogeneic transplantation for primary myelofibrosis between 1989 and 2002, from the database of the Center for International Bone Marrow Transplant Research (CIBMTR). The median age was 47 years (range: 18-73 years). Donors were HLA identical siblings in 162 patients, unrelated individuals in 101 patients, and HLA nonidentical family members in 26 patients. Patients were treated with a variety of conditioning regimens and graft-versus-host disease (GVHD) prophylaxis regimens. Splenectomy was performed in 65 patients prior to transplantation. The 100-day treatment-related mortality was 18% for HLA identical sibling transplants, 35% for unrelated transplants, and 19% for transplants from alternative related donors. Corresponding 5-year overall survival (OS) rates were 37%, 30%, and 40%, respectively. DFS rates were 33%, 27%, and 22%, respectively. DFS for patients receiving reduced-intensity transplants was comparable: 39% for HLA identical sibling donors and 17% for unrelated donors at 3 years. In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival (RFS) in about one-third of patients.

AB - Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small series have reported long-term disease-free survival (DSF) after allogeneic hematopoietic cell transplantation (HCT). In this study, we analyze the outcomes of 289 patients receiving allogeneic transplantation for primary myelofibrosis between 1989 and 2002, from the database of the Center for International Bone Marrow Transplant Research (CIBMTR). The median age was 47 years (range: 18-73 years). Donors were HLA identical siblings in 162 patients, unrelated individuals in 101 patients, and HLA nonidentical family members in 26 patients. Patients were treated with a variety of conditioning regimens and graft-versus-host disease (GVHD) prophylaxis regimens. Splenectomy was performed in 65 patients prior to transplantation. The 100-day treatment-related mortality was 18% for HLA identical sibling transplants, 35% for unrelated transplants, and 19% for transplants from alternative related donors. Corresponding 5-year overall survival (OS) rates were 37%, 30%, and 40%, respectively. DFS rates were 33%, 27%, and 22%, respectively. DFS for patients receiving reduced-intensity transplants was comparable: 39% for HLA identical sibling donors and 17% for unrelated donors at 3 years. In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival (RFS) in about one-third of patients.

KW - Allogeneic transplantation

KW - Myelofibrosis

UR - http://www.scopus.com/inward/record.url?scp=75749125700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749125700&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2009.10.025

DO - 10.1016/j.bbmt.2009.10.025

M3 - Article

C2 - 19879949

AN - SCOPUS:75749125700

VL - 16

SP - 358

EP - 367

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 3

ER -